Advanced Solid Tumors
iTeos Belgium supports clinical research in advanced solid tumors across multiple investigational combinations, with attention to treatment settings where disease control remains challenging. The portfolio includes studies in broadly defined solid tumors as well as more specific advanced malignancies.
- Oncology
- Advanced solid tumors
- Solid tumors
The sponsor’s trial activity reflects interest in therapeutic strategies for patients with advanced disease, including combination approaches intended to address resistant or refractory tumor settings.
Non-Small Cell Lung Cancer
Clinical research includes nonsquamous non-small cell lung cancer, with particular focus on metastatic disease and patients who have progressed after prior immunotherapy. This area highlights interest in treatment-resistant lung cancer populations.
- Metastatic non-small cell lung cancer
- Nonsquamous histology
- Post-immunotherapy disease
Trials in this setting examine combinations used in first-line and previously treated disease, underscoring a therapeutic focus on improving outcomes in advanced lung cancer.
Immuno-Oncology Combinations
The sponsor is actively involved in immuno-oncology research centered on combinations with checkpoint-based therapies, including agents paired with pembrolizumab and dostarlimab. These studies span several tumor types and resistance contexts.
- Checkpoint inhibitor combinations
- PD-1 / PD-L1 pathways
- Combination immunotherapy
Research activity in this domain extends to tumors such as head and neck squamous cell carcinoma and metastatic melanoma, in addition to lung cancer and broader solid tumors.
Novel Therapeutic Targets
iTeos Belgium funds studies of emerging agents including adenosine pathway-directed therapy and other novel anticancer mechanisms. The portfolio also includes combinations with standard chemotherapy backbones such as carboplatin and pemetrexed.
- Adenosine receptor targeting
- Investigational anticancer agents
- Chemotherapy combinations
These programs indicate sustained interest in integrating new therapeutic approaches with established oncology regimens across advanced malignancies.
